Floatz logo

Xuefu-Zhuyu

Headache

Zhong WangPhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
89/ 100

Competitive context

14 Active assets in the Headache cohort.

Asset / SponsorPhaseRating
Topamax
University of Minnesota
Phase 4BBB
LIDOCAINE
Daniel A Tonetti, MD
Phase 4BBB
Treximet®
Danish Headache Center
Phase 4BBB
Prochlorperazine
Wake Forest University Health Sciences
Phase 4BBB
PROPOFOL
Medical College of Wisconsin
Phase 4BBB

View all 50 →

Same molecule, other indications

Xuefu-Zhuyu is also rated in:

insomniaDormant
BB
Indicative ·
65 / 100
View asset →
endometriosisDormant
BB
Indicative ·
65 / 100
View asset →
coronary artery disorderDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →